



The invention relates to novel carbamoylaseheterocycles which are of interest in the form of potential physiologically active agents (receptor agonists, antagonists and modulators, ferment inhibitors, oncolytics, antibacterial and antiparasitic agents, etc), to a focused library comprising carbamoylase-heterocycles, a pharmaceutical composition containing said carbamoylase-heterocycles in the form of an active substance and to methods for the production and the use thereof.

The inventive carbamoylase-heterocycles are of general formula 1, wherein W is 6-oxopiperazine, [1,4] diazepan, [1,4] tiazepan or [1,4] oxazepan cycle annelated with at least one optionally substituted or optionally condensed heterocycle Q; R^1 , R^2 , R^3 are independently of each other a hydrogen atom, an inert substituent, an optionally substituted C_1 - C_6 alkyl, an optionally substituted C_3 - C_8 cycloalkyl, an optionally substituted phenyl, an optionally substituted aryl and an optionally substituted heterocycle; Q is pyrrole, pyrazole, imidazole, tiazole, pyrrolidine, indonole, benzofuran, 4,5,6,7-tetrahydrobenzothiophene, thieno[3,2-b]pyrrole, furo[3,2-b]pyrrole, thieno[2,3-b]pyrrole, benzimidazole, pyridine, quinoline or 1,2,3,4-tetrahydroisoquinoline cycle.